Southern Med Law Logo

SOUTHERN MED LAW

• Forever Pursuing Justice•

Weight Loss Drugs Litigation

Drugs such as Ozempic (semaglutide), Wegovy and Munjaro have rapidly grown in popularity for chronic weight management since 2021. However, concerns over serious gastrointestinal side effects and other safety issues have begun mounting. As injured users increasingly take legal action against the drug’s manufacturer Novo Nordisk, understanding the background and current status of Ozempic litigation is important. 

Ozempic Litigation

At Southern Med Law, we are uniquely equipped to build strong weight loss drug injury cases while compassionately guiding injury victims toward justice. Led by our founder Dr. François Blaudeau, our attorneys know how to efficiently consolidate resources with fellow top plaintiffs’ firms when multidistrict litigation takes shape. Meanwhile, insights from other doctors allow us to truly grasp the pain and life disruption stemming from severe gastric complications while simplifying complex health details for juries.

This rare combination of legal talent and medical understanding drives our tireless efforts to reveal key facts, establish accountability, and obtain fair remedies for those harmed by Ozempic, wagovy and munjaro side effects. From fully analyzing your case during initial consultations to advising on potential settlement offers down the road, Southern Med Law remains dedicated to patients who have been devastated by drugs such as Ozempic that were marketed as wonder solutions.

Southern Med Law Logo

Background Information

Ozempic contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist that regulates blood sugar levels and appetite. It was first introduced by the pharmaceutical company Novo Nordisk in 2017 for the treatment of type 2 diabetes, at dosages of 0.5 mg or 1 mg injected subcutaneously once weekly. Then in 2021, the FDA approved Ozempic for chronic weight management in obese and overweight adults at a higher dosage of 2.4 mg injected once weekly.

At this point, the medication contains the same active ingredient as Novo Nordisk’s type 2 diabetes drug Victoza. However, Ozempic’s approval for weight loss now opens it to a far larger patient population. In 2022 alone, more than 600,000 people filled new Ozempic prescriptions just within the Medicare system. However, the rapidly expanding user base has brought intensifying scrutiny over side effects.

Southern Med Law Logo

Recent Developments

In 2022, the FDA required Novo Nordisk to add new warnings to Ozempic labeling about a higher risk of both thyroid cancer and pancreatitis. Federal regulators also continue closely evaluating post-marketing adverse event reports pointing to additional concerns like severe gastrointestinal problems.

In turn, lawsuits alleging failure to warn about Ozempic’s dangers have now been brought against Novo Nordisk nationwide. The cases center on injuries to the gastrointestinal system including pancreatitis, pancreatic cancer, and related issues which patients contend were not adequately disclosed initially. Psychological side effects like suicidal thoughts have also begun emerging as grounds for legal action.

Southern Med Law Logo

Current Lawsuit Status

Currently in the early stages, the Ozempic litigation involves a growing number of plaintiffs who filed lawsuits after experiencing life-altering injuries. Their cases commonly allege that Novo Nordisk failed to sufficiently warn doctors and patients about the drug’s potential risks before winning FDA approval and launching their extensive marketing efforts.

Patients filing lawsuits report developing chronic conditions like gastroparesis, gallbladder disease, and pancreatitis while taking Ozempic. The injuries alleged often require hospitalization, surgical intervention, and extended medical treatment. The lawsuits also seek financial compensation for lost income and reduced quality of life resulting from these newly diagnosed ailments.

Southern Med Law Logo

History of Ozempic Litigation

Ozempic first gained FDA approval in 2017 for the management of type 2 diabetes without containing black box warnings, the agency’s strongest safety notice. In the subsequent years, mounting post-marketing reports began to surface about adverse effects from Ozempic treatment both among diabetes and new weight loss patients.

These developments then prompted the FDA to require updated warnings on the Ozempic label pointing to risks like pancreatitis and precancerous gallbladder lesions. However, lawsuits filed against Novo Nordisk argue that these dangers should have been flagged much earlier. Patients contend earlier disclosure would have significantly impacted their decision to begin Ozempic in the first place.

Southern Med Law Logo

Allegations and Side Effects

One of the most serious complications arising in Ozempic patients involves gastroparesis, a digestive disorder causing delayed stomach emptying. The symptoms of this condition can severely reduce their quality of life:

  • Frequent nausea, vomiting, bloating, and related gastrointestinal distress.
  • Inability to properly digest solid foods and maintain nutrition.
  • Substantial unintended weight loss and dehydration.
  • Repeated hospitalizations for supportive medical care.

Additionally, research shows heightened risks of gallbladder disease tied to Ozempic usage:

  • Studies link semaglutide to higher rates of gallstones and related issues.
  • Up to 4% of long-term Ozempic patients may develop gallbladder sludge or stones.
  • Many ultimately require surgery for gallbladder removal due to complications.

Beyond the gastrointestinal realm, potential psychological side effects have arisen:

  • FDA investigating post-marketing reports of suicidal thoughts and behaviors.
  • Lawsuits also allege later onset of kidney disease, and cardiovascular problems.
  • Patients contend Novo Nordisk concealed early knowledge of many risks.
Southern Med Law Logo

Novo Nordisk’s Response

In response to the emerging litigation, Novo Nordisk has broadly stated they acted responsibly in disclosing known risks to health authorities and the public. They argue that the label updates with enhanced warnings about cancers and pancreatitis as more data emerged demonstrate appropriate pharmacovigilance and monitoring of post-approval safety.

The company also points to the extensive information included in the drug’s prescribing information. However, lawsuits counter that these details still fail to capture the full scope of dangers, particularly the severity of gastrointestinal side effects impacting quality of life. Novo Nordisk also stresses physicians’ role in weighing Ozempic’s risks versus benefits for each individual patient.

Southern Med Law Logo

Who Can File an Ozempic Lawsuit?

Those experiencing severe or chronic gastrointestinal injuries while taking Ozempic often have grounds to pursue legal action. Patients later diagnosed with conditions like gastroparesis or colonic obstruction that continue battling digestive problems may warrant cases.

Additionally, patients who suffered psychological side effects like suicidal thoughts or kidney damage may have valid Ozempic claims as well. However, speaking to an attorney can help fully evaluate the viability and strength of potential cases on an individual basis.

Southern Med Law Logo

Potential Compensation from Ozempic Litigation

Financial recovery from an Ozempic lawsuit can include coverage of past and future medical costs required for testing and treatment of injuries. Successful verdicts may also award lost income stemming from being unable to work during prolonged recovery. Additional damages like reimbursement for emotional distress and reduced enjoyment of life may be warranted too.

If gross negligence involving illegal or reckless Ozempic marketing and distribution tactics can be demonstrated, substantial punitive damages vastly exceeding simple compensation may be possible as well. An experienced attorney can advise on realistic compensation estimates based on specific case circumstances.

Southern Med Law Logo

Future of Ozempic Litigation

Considering the widespread usage and mounting accounts of debilitating injuries, consolidated nationwide class action lawsuits seem a probable next step in efficiently moving many Ozempic claims through the legal system simultaneously.

The creation of a federal multidistrict litigation (MDL) consolidating pretrial processes around the country also appears likely. These specialized MDL courts have commonly emerged in major drug injury cases like with Eliquis, Zantac, and 3M earplugs currently. The Ozempic litigation may soon follow a similar trajectory allowing plaintiffs to present their arguments and expert evidence on a national scale.

Southern Med Law Logo

How Southern Med Law Can Help

With decades of experience handling major cases against pharmaceutical giants over drug injuries and aggressive marketing tactics, Southern Med Law stands ready to support Ozempic users nationwide. Our firm has successfully represented clients in litigation involving popular diabetes medications like Invokana and Actos historically as well.

This background allows us to thoroughly investigate Ozempic complications, determine root causes and accountability, and fight for maximum financial compensation through settlements or jury verdicts for those grappling with life-changing conditions.

If Ozempic usage resulted in health declines for you or a loved one, please contact us today at (205) 564-2741 for a free consultation on your legal options. We will evaluate your case details carefully, answer all questions, and outline the best path forward for pursuing justice.